132 related articles for article (PubMed ID: 18728965)
1. Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab.
Liu CY; Teng HW; Lirng JF; Chiou TJ; Chen PM; Hsiao LT
Leuk Lymphoma; 2008 Oct; 49(10):2018-21. PubMed ID: 18728965
[No Abstract] [Full Text] [Related]
2. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
[TBL] [Abstract][Full Text] [Related]
3. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
4. Durable remission of intravascular lymphoma with central nervous system involvement following chemotherapy and rituximab.
Go A; Venugopal P; Loew J; Djordjevic D
Clin Adv Hematol Oncol; 2006 Jun; 4(6):439-41. PubMed ID: 16981666
[No Abstract] [Full Text] [Related]
5. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
Abramson JS; Hellmann M; Barnes JA; Hammerman P; Toomey C; Takvorian T; Muzikansky A; Hochberg EP
Cancer; 2010 Sep; 116(18):4283-90. PubMed ID: 20564149
[TBL] [Abstract][Full Text] [Related]
6. [Relationship between clinopathological features and outcome of rituximab treatment for diffuse large B-cell lymphoma].
Zhang HY; Guan ZZ; Wang B; Huang HQ; Xia ZJ; Lin TY
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):381-4. PubMed ID: 18953841
[TBL] [Abstract][Full Text] [Related]
7. Isolated central nervous system relapse in a patient with diffuse large B cell lymphoma.
Sato K; Uchiyama M
BMJ Case Rep; 2012 Jan; 2012():. PubMed ID: 22665914
[No Abstract] [Full Text] [Related]
8. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
9. Rituximab maintenance therapy in central nervous system lymphoma?
Murawski N; Pfreundschuh M
Leuk Lymphoma; 2009 Oct; 50(10):1555-6. PubMed ID: 19757314
[No Abstract] [Full Text] [Related]
10. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
11. Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era?
Cheah CY; Seymour JF
Leuk Lymphoma; 2014 Mar; 55(3):471-3. PubMed ID: 23906017
[No Abstract] [Full Text] [Related]
12. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
[TBL] [Abstract][Full Text] [Related]
13. Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.
Tomita N; Takasaki H; Ishiyama Y; Kishimoto K; Ishibashi D; Koyama S; Ishii Y; Takahashi H; Numata A; Watanabe R; Tachibana T; Ohshima R; Hagihara M; Hashimoto C; Takemura S; Taguchi J; Fujimaki K; Sakai R; Motomura S; Ishigatsubo Y
Leuk Lymphoma; 2015 Mar; 56(3):725-9. PubMed ID: 24913502
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients.
Zinzani PL; Pellegrini C; Derenzini E; Argnani L; Pileri S
Hematol Oncol; 2013 Dec; 31(4):223-4. PubMed ID: 23620452
[No Abstract] [Full Text] [Related]
15. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
Papageorgiou SG; Diamantopoulos P; Levidou G; Angelopoulou MK; Economopoulou P; Efthimiou A; Constantinou N; Katsigiannis A; Korkolopoulou P; Pappa V; Economopoulou C; Georgiou G; Dimou M; Tsirigotis P; Kyrtsonis MC; Kotsianidis I; Kalpadakis C; Dimopoulos MA; Beris P; Meletis J; Pangalis GA; Dervenoulas J; Panayiotidis P; Vassilakopoulos TP
Hematol Oncol; 2013 Mar; 31(1):10-7. PubMed ID: 22610484
[TBL] [Abstract][Full Text] [Related]
16. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis.
Zhang J; Chen B; Xu X
Leuk Lymphoma; 2014 Mar; 55(3):509-14. PubMed ID: 23741977
[TBL] [Abstract][Full Text] [Related]
17. The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma.
Mitrovic Z; Bast M; Bierman PJ; Bociek RG; Vose JM; Chan WC; Armitage JO
Br J Haematol; 2012 May; 157(3):401-3. PubMed ID: 22224728
[No Abstract] [Full Text] [Related]
18. Intra-vascular large B-cell lymphoma revealed by a nephrotic syndrome: a one year remission induced by a high frequency CHOP and rituximab.
Girard T; Nochy D; Montravers F; Der Sahakian G; Fior R; Galanaud P; Boué F
Leuk Lymphoma; 2004 Aug; 45(8):1703-5. PubMed ID: 15370230
[TBL] [Abstract][Full Text] [Related]
19. Complete remission of primary cutaneous intravascular large B-cell lymphoma with R-CHOP followed by rituximab monotherapy.
Pantelaki I; Tigges C; Nußbaum T; Oellig F; Wieland U; Kreuter A
Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28508527
[No Abstract] [Full Text] [Related]
20. Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma.
Saito B; Shiozawa E; Usui T; Nakashima H; Maeda T; Hattori N; Shimozuma J; Adachi D; Yamochi-Onizuka T; Takimoto M; Nakamaki T; Ota H; Tomoyasu S
Leukemia; 2007 Dec; 21(12):2563-6. PubMed ID: 17597802
[No Abstract] [Full Text] [Related]
[Next] [New Search]